Sandoz settlement with end payers in US generic drug litigation gets preliminary nod
MLex Summary: Sandoz’s $275 million settlement with end payers to resolve US price-fixing claims over generic pharmaceuticals has been granted preliminary approval by a federal judge.See attached file. ...To view the full article, register now.
Already a subscriber? Click here to view full article